Anupam Rasayan India Ltd. has reported its financial results for the quarter and year ended March 31, 2026. The company announced a final dividend of INR 1.5 per share (15% of face value) for the FY2025-26 period. Additionally, the Board has approved the acquisition of a 74.20% stake in Bliss GVS Pharma Limited and confirmed the raising of INR 160 crore through the private placement of non-convertible debentures.
Financial Performance for FY2026
For the financial year ended March 31, 2026, Anupam Rasayan reported standalone revenue of INR 16,955.30 million and a profit after tax of INR 1,613.96 million. On a consolidated basis, the company delivered a stronger performance with a total revenue of INR 23,836.29 million and a consolidated profit after tax of INR 2,221.99 million, reflecting the company’s sustained growth trajectory over the past fiscal year.
Strategic Acquisition and Funding
The company has embarked on a major expansion strategy by approving the acquisition of 74.20% of the equity share capital and control of Bliss GVS Pharma Limited. To support its capital requirements and growth initiatives, the Board also sanctioned the issuance of 16,000 Secured, Rated, Unlisted, Redeemable, Non-Convertible Debentures (NCDs), aggregating to INR 160 crore on a private placement basis.
Leadership Changes and Corporate Governance
Alongside its financial and strategic updates, the company announced the resignation of Mr. Vishal Thakkar from his position as Deputy Chief Financial Officer and Key Managerial Personnel, effective immediately. Furthermore, the Board has recommended a final dividend of INR 1.5 per equity share, subject to approval by shareholders at the forthcoming 23rd Annual General Meeting.
Auditor and Management Updates
The company confirmed that Natvarlal Vepari & Co. issued audit reports with an unmodified opinion on the financial results. Additionally, K.B. Daliya & Associates has been re-appointed as the Internal Auditor, and Bhanwarlal Gurjar & Co. as the Cost Auditor for the upcoming 2026-27 financial year, ensuring continued oversight of internal processes and cost records.
Source: BSE
